牛津分型队列证据支持对IgA肾病局灶节段性肾小球硬化进行亚分类的临床价值
该研究在牛津分型患者队列中评估IgA肾病局灶节段性肾小球硬化(FSGS)病变的亚分类可重复性及其与临床表现和结局的相关性。137例伴节段性硬化或粘连(S1)患者中,足细胞肥大占38%、透明变性占10%、足细胞内吸收滴占9%、尖端病变占7%、门周硬化占3%、内皮泡沫细胞占2%。足细胞肥大和尖端病变与初始蛋白尿较强相关,在未免疫抑制患者中与更快的肾功能下降和更差的复合事件生存相关。
要点
- 足细胞肥大和尖端病变在IgA肾病中可重复识别,并与初始蛋白尿较强相关。
- 未免疫抑制的S1患者中,伴足细胞肥大或尖端病变者肾功能下降更快、复合事件生存更差。
- 伴足细胞肥大或尖端病变者接受免疫抑制治疗与更好的肾脏生存相关。
核心结论
- IgA肾病中足细胞肥大或尖端病变(足细胞损伤标志)可重复识别,与蛋白尿强相关,未治疗患者预后更差,支持在牛津分型S评分之外报告足细胞病变特征。
研究设计与样本
- 研究评估牛津分型患者队列中FSGS病变,将137例伴节段性硬化或粘连(S1)的IgA肾病患者进行亚分类,并与临床表现和结局进行相关性分析。
主要发现
- 137例S1患者中,足细胞肥大占38%、透明变性占10%、足细胞内吸收滴占9%、尖端病变占7%、门周硬化占3%、内皮泡沫细胞占2%。
- 尖端病变、透明变性和门周硬化的可重复性为良好或优秀;足细胞肥大为中等;吸收滴、仅粘连和内皮泡沫细胞为差。
- 足细胞肥大和尖端病变与初始蛋白尿较强相关。
- 未免疫抑制患者随访中,伴足细胞肥大或尖端病变者较不伴这些特征的S1患者及无FSGS者肾功能下降更快、复合事件生存更差。
- 伴足细胞肥大或尖端病变者,免疫抑制治疗与更好的肾脏生存相关。
临床怎么用
- 原文结论支持在牛津分型S评分之外报告足细胞病变特征,未给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Focal segmental glomerulosclerosis (FSGS) is a common finding in IgA nephropathy (IgAN). Here we assessed FSGS lesions in the Oxford Classification patient cohort and correlated histology with clinical presentation and outcome to determine whether subclassification of the S score in IgAN is reproducible and of clinical value. Our subclassification of lesions in 137 individuals with segmental glomerulosclerosis or adhesion (S1) identified 38% with podocyte hypertrophy, 10% with hyalinosis, 9% with resorption droplets within podocytes, 7% with tip lesions, 3% with perihilar sclerosis, and 2% with endocapillary foam cells. Reproducibility was good or excellent for tip lesions, hyalinosis, and perihilar sclerosis; moderate for podocyte hypertrophy; and poor for resorption droplets, adhesion only, and endocapillary foam cells. Podocyte hypertrophy and tip lesions were strongly associated with greater initial proteinuria. During follow-up of patients without immunosuppression, those with these features had more rapid renal function decline and worse survival from a combined event compared to S1 patients without such features and those without FSGS. Also in individuals with podocyte hypertrophy or tip lesions, immunosuppressive therapy was associated with better renal survival. In IgA nephropathy, the presence of podocyte hypertrophy or tip lesions, markers of podocyte injury, were reproducible. These features are strongly associated with proteinuria and, in untreated patients, carry a worse prognosis. Thus, our findings support reporting podocytopathic features alongside the S score of the Oxford Classification.
引用
- Bellur SS, Lepeytre F, Vorobyeva O, et al. Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int. 2016. PMID: 27914703. doi:10.1016/j.kint.2016.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。